Live biotherapeutic product IBP-9414 (L. reuteri) in very low birth weight infants: the Connection Study - PubMed
11 hours ago
- #probiotics
- #neonatal health
- #clinical trial
- The Connection Study evaluated the efficacy and safety of IBP-9414 (L. reuteri) in very low birth weight (VLBW) infants.
- IBP-9414 did not significantly reduce necrotizing enterocolitis (NEC) incidence or improve sustained feeding tolerance (SFT).
- All-cause mortality was reduced with IBP-9414 (6.2% vs. 8.5% in placebo group, RR: 0.73, p = 0.036).
- IBP-9414 was found to be safe, with no evidence of the product in blood cultures.
- The study supports the use of IBP-9414 in VLBW infants to safely reduce mortality and morbidity.